跳到正文
原文
Medical Xpress·· 2026-10-12AI 评分36

双触发药物靶向“僵尸”癌细胞,提高清除精准度

Two-trigger drugs target 'zombie' cancer cells with sharper aim

AI 导读

研究团队在 Advanced Science 发表双分子锁前体药物研究,通过光与β-半乳糖苷酶序贯触发,显著提升对衰老癌细胞的清除选择性。体外及类器官模型显示,该策略逆转普通多柔比星毒性偏好,衰老类器官中组合处理增加细胞死亡,而未衰老模型中影响不显著。该方案尚未在动物或患者中测试。

正文
Two-lock drugs use light to target senescent cancer cells in lab tests
Design of SA-β-gal-sensitive probes for targeting senescent cells. Credit: Advanced Science (2026). DOI: 10.1002/advs.78139

Stopping a cancer cell from dividing does not necessarily make it harmless. Chemotherapy can leave behind living, senescent cells. These 'zombie' cells can release inflammatory signals, helping tumors resist treatment. Drugs that eliminate these lingering cells could help, but they can also harm other cells.

The problem researchers needed to address is that the enzyme commonly used to identify senescent cells also works in some non-senescent tissues, creating a risk of unwanted drug activation. And although light can control where a drug activates, using light alone could act on any cell within the illuminated area. Could a sequential light–enzyme switch combination improve selective targeting?

Mengyang Chang and colleagues at institutions including China's Eastern Institute of Technology and Xinqiao Hospital developed experimental drugs with two molecular locks that are designed to be opened with the two keys: light and an enzyme. In laboratory tests, the combination made the drugs more selective about which cancer cells they killed. The findings are published in the journal Advanced Science.

Why light needs a second key

The researchers paired illumination control with beta-galactosidase, an enzyme whose activity often rises in senescent cells. It can remove a sugar-based covering attached to a drug, releasing the active ingredient. But the enzyme also works in cells that are not senescent, making it an imperfect key on its own.

The new design makes the two triggers work in sequence. Near-ultraviolet light removes a protective group that blocks the enzyme's access; the enzyme can then remove the remaining covering.

The team first tested this arrangement with a fluorescent molecule. Light or enzyme treatment alone produced little fluorescence, while the combination released a product that glowed strongly blue. Chemical analysis confirmed that the release happened in two steps.

The next question was whether those locks could change which cells a drug kills.

Two-lock drugs use light to target senescent cancer cells in lab tests
(A) Schematic illustration of the dual-trigger mechanism (B) Predicted binding poses of 6-(2-nitrobenzyl)-β-galactose and β-galactose with β-galactosidase (C) Fluorescence images (λex = 340nm) of different treatment groups. Credit: Advanced Science (2026). DOI: 10.1002/advs.78139

Changing a drug's preference

The researchers applied the design to the chemotherapy drug doxorubicin, creating a modified compound called LS-D.

In a breast cancer cell model, ordinary doxorubicin was more toxic to cells that had not entered senescence. With illumination, LS-D reversed that preference. The concentration needed to halve measured viability was roughly eight times as high in nonsenescent cells as in their senescent counterparts.

To check whether the enzyme helped unlock LS-D inside cells, the researchers reduced its production in senescent lung cancer cells. That weakened the illuminated drug's killing effect. A second experimental drug also became more selective for senescent cells with the two-lock design.

These tests compared cancer cells in different states, so they do not establish that healthy tissue would be spared. The locks were also imperfect: LS-D retained some toxicity without light at higher concentrations.

A test in miniature tumors

The team then moved beyond flat cell cultures to three-dimensional organoids grown from lung tumors donated by five patients. They used chemotherapy to induce senescence and compared the treatment's effects with those in organoids that had not undergone that change.

In the senescent organoids, LS-D combined with five minutes of illumination increased cell death. Light or LS-D alone had little effect under those conditions.

In organoids that had not been induced into senescence, the combination did not significantly reduce the proportion of living tissue. Unmodified doxorubicin, by comparison, reduced that proportion in both groups.

The approach has yet to be tested in animals or patients. Its light-sensitive lock also presents a practical obstacle: Near-ultraviolet light penetrates tissue poorly and may cause damage at higher doses or with longer exposure.

To address this, the authors propose developing compounds responsive to more deeply penetrating light or delivering illumination through optical fibers. Animal studies would need to show whether those approaches preserve the selectivity seen in the laboratory and whether the added control actually reduces harm to healthy tissue.

Written for you by our author Andrew Zinin, edited by Lisa Lock, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

Mengyang Chang et al, Orthogonal Light‐ and Enzyme‐Triggered and‐Gate Prodrugs for Senolytic Therapy, Advanced Science (2026). DOI: 10.1002/advs.78139

Journal information: Advanced Science

Key medical concepts

Doxorubicin

Who's behind this story?

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: Two-trigger drugs target 'zombie' cancer cells with sharper aim (2026, October 12) retrieved 12 October 2026 from https://medicalxpress.com/news/2026-10-trigger-drugs-zombie-cancer-cells.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com